CU22545A1
(es)
|
1994-11-18 |
1999-03-31 |
Centro Inmunologia Molecular |
Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
|
US4708871A
(en)
|
1983-03-08 |
1987-11-24 |
Commonwealth Serum Laboratories Commission |
Antigenically active amino acid sequences
|
NZ207394A
(en)
|
1983-03-08 |
1987-03-06 |
Commw Serum Lab Commission |
Detecting or determining sequence of amino acids
|
WO1984003506A1
(en)
|
1983-03-08 |
1984-09-13 |
Commw Serum Lab Commission |
Antigenically active amino acid sequences
|
US4943533A
(en)
|
1984-03-01 |
1990-07-24 |
The Regents Of The University Of California |
Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
|
DE3587814T2
(de)
|
1985-03-30 |
1994-11-10 |
Marc Ballivet |
Verfahren zum erhalten von dns, rns, peptiden, polypeptiden oder proteinen durch dns-rekombinant-verfahren.
|
NZ215865A
(en)
|
1985-04-22 |
1988-10-28 |
Commw Serum Lab Commission |
Method of determining the active site of a receptor-binding analogue
|
US4676980A
(en)
|
1985-09-23 |
1987-06-30 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Target specific cross-linked heteroantibodies
|
US6548640B1
(en)
|
1986-03-27 |
2003-04-15 |
Btg International Limited |
Altered antibodies
|
US5763192A
(en)
|
1986-11-20 |
1998-06-09 |
Ixsys, Incorporated |
Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique
|
IL85035A0
(en)
|
1987-01-08 |
1988-06-30 |
Int Genetic Eng |
Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
|
JP3101690B2
(ja)
|
1987-03-18 |
2000-10-23 |
エス・ビィ・2・インコーポレイテッド |
変性抗体の、または変性抗体に関する改良
|
US5606040A
(en)
|
1987-10-30 |
1997-02-25 |
American Cyanamid Company |
Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
|
US5770701A
(en)
|
1987-10-30 |
1998-06-23 |
American Cyanamid Company |
Process for preparing targeted forms of methyltrithio antitumor agents
|
US5266684A
(en)
|
1988-05-02 |
1993-11-30 |
The Reagents Of The University Of California |
Peptide mixtures
|
US5571689A
(en)
|
1988-06-16 |
1996-11-05 |
Washington University |
Method of N-acylating peptide and proteins with diheteroatom substituted analogs of myristic acid
|
US5223409A
(en)
|
1988-09-02 |
1993-06-29 |
Protein Engineering Corp. |
Directed evolution of novel binding proteins
|
US5663143A
(en)
|
1988-09-02 |
1997-09-02 |
Dyax Corp. |
Engineered human-derived kunitz domains that inhibit human neutrophil elastase
|
EP0368684B2
(en)
|
1988-11-11 |
2004-09-29 |
Medical Research Council |
Cloning immunoglobulin variable domain sequences.
|
DE3920358A1
(de)
|
1989-06-22 |
1991-01-17 |
Behringwerke Ag |
Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
|
CA2066428C
(en)
|
1989-09-08 |
2000-11-28 |
Bert Vogelstein |
Structural alterations of the egf receptor gene in human gliomas
|
CA2026147C
(en)
|
1989-10-25 |
2006-02-07 |
Ravi J. Chari |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
US5208020A
(en)
|
1989-10-25 |
1993-05-04 |
Immunogen Inc. |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
US6075181A
(en)
|
1990-01-12 |
2000-06-13 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
US6150584A
(en)
|
1990-01-12 |
2000-11-21 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
US5427908A
(en)
|
1990-05-01 |
1995-06-27 |
Affymax Technologies N.V. |
Recombinant library screening methods
|
US5723286A
(en)
|
1990-06-20 |
1998-03-03 |
Affymax Technologies N.V. |
Peptide library and screening systems
|
US5770429A
(en)
|
1990-08-29 |
1998-06-23 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
US5698426A
(en)
|
1990-09-28 |
1997-12-16 |
Ixsys, Incorporated |
Surface expression libraries of heteromeric receptors
|
US5770434A
(en)
|
1990-09-28 |
1998-06-23 |
Ixsys Incorporated |
Soluble peptides having constrained, secondary conformation in solution and method of making same
|
ATE176239T1
(de)
|
1990-11-21 |
1999-02-15 |
Iterex Pharma Lp |
Synthese äquimolarer mischungen vielzähliger oligomere, speziell oligopeptidmischungen
|
DK0564531T3
(da)
|
1990-12-03 |
1998-09-28 |
Genentech Inc |
Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber
|
US5571894A
(en)
|
1991-02-05 |
1996-11-05 |
Ciba-Geigy Corporation |
Recombinant antibodies specific for a growth factor receptor
|
LU91067I2
(fr)
|
1991-06-14 |
2004-04-02 |
Genentech Inc |
Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
|
GB9114948D0
(en)
|
1991-07-11 |
1991-08-28 |
Pfizer Ltd |
Process for preparing sertraline intermediates
|
US5587458A
(en)
|
1991-10-07 |
1996-12-24 |
Aronex Pharmaceuticals, Inc. |
Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
|
US5270170A
(en)
|
1991-10-16 |
1993-12-14 |
Affymax Technologies N.V. |
Peptide library and screening method
|
WO1993008829A1
(en)
|
1991-11-04 |
1993-05-13 |
The Regents Of The University Of California |
Compositions that mediate killing of hiv-infected cells
|
GB9300059D0
(en)
|
1992-01-20 |
1993-03-03 |
Zeneca Ltd |
Quinazoline derivatives
|
CA2372813A1
(en)
|
1992-02-06 |
1993-08-19 |
L.L. Houston |
Biosynthetic binding protein for cancer marker
|
JP3095175B2
(ja)
|
1992-11-13 |
2000-10-03 |
アイデック ファーマシューティカルズ コーポレイション |
B細胞リンパ腫の治療のためのヒトbリンパ球限定分化抗原に対するキメラ抗体と放射能標識抗体の療法利用
|
US5635483A
(en)
|
1992-12-03 |
1997-06-03 |
Arizona Board Of Regents Acting On Behalf Of Arizona State University |
Tumor inhibiting tetrapeptide bearing modified phenethyl amides
|
US5780588A
(en)
|
1993-01-26 |
1998-07-14 |
Arizona Board Of Regents |
Elucidation and synthesis of selected pentapeptides
|
WO1994029351A2
(en)
|
1993-06-16 |
1994-12-22 |
Celltech Limited |
Antibodies
|
GB9314893D0
(en)
|
1993-07-19 |
1993-09-01 |
Zeneca Ltd |
Quinazoline derivatives
|
ATE207366T1
(de)
|
1993-12-24 |
2001-11-15 |
Merck Patent Gmbh |
Immunokonjugate
|
US5654307A
(en)
|
1994-01-25 |
1997-08-05 |
Warner-Lambert Company |
Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
|
IL112248A0
(en)
|
1994-01-25 |
1995-03-30 |
Warner Lambert Co |
Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
|
IL112249A
(en)
|
1994-01-25 |
2001-11-25 |
Warner Lambert Co |
Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
|
US5773001A
(en)
|
1994-06-03 |
1998-06-30 |
American Cyanamid Company |
Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
GB9508538D0
(en)
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quinazoline derivatives
|
DE19516776A1
(de)
|
1995-05-10 |
1996-11-14 |
Boehringer Ingelheim Int |
Chromatin-Regulatorgene
|
US5747498A
(en)
|
1996-05-28 |
1998-05-05 |
Pfizer Inc. |
Alkynyl and azido-substituted 4-anilinoquinazolines
|
US5712374A
(en)
|
1995-06-07 |
1998-01-27 |
American Cyanamid Company |
Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
|
EP0831880A4
(en)
|
1995-06-07 |
2004-12-01 |
Imclone Systems Inc |
ANTIBODIES AND FRAGMENTS OF ANTIBODIES INHIBITING TUMOR GROWTH
|
US5714586A
(en)
|
1995-06-07 |
1998-02-03 |
American Cyanamid Company |
Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
|
US6140332A
(en)
|
1995-07-06 |
2000-10-31 |
Novartis Ag |
Pyrrolopyrimidines and processes for the preparation thereof
|
US6267958B1
(en)
|
1995-07-27 |
2001-07-31 |
Genentech, Inc. |
Protein formulation
|
US5760041A
(en)
|
1996-02-05 |
1998-06-02 |
American Cyanamid Company |
4-aminoquinazoline EGFR Inhibitors
|
GB9603095D0
(en)
|
1996-02-14 |
1996-04-10 |
Zeneca Ltd |
Quinazoline derivatives
|
GB9603256D0
(en)
|
1996-02-16 |
1996-04-17 |
Wellcome Found |
Antibodies
|
PL190489B1
(pl)
|
1996-04-12 |
2005-12-30 |
Warner Lambert Co |
Nieodwracalne inhibitory kinaz tyrozyny, kompozycja farmaceutyczna je zawierająca i ich zastosowanie
|
EP0912559B1
(en)
|
1996-07-13 |
2002-11-06 |
Glaxo Group Limited |
Fused heterocyclic compounds as protein tyrosine kinase inhibitors
|
ID18494A
(id)
|
1996-10-02 |
1998-04-16 |
Novartis Ag |
Turunan pirazola leburan dan proses pembuatannya
|
US6002008A
(en)
|
1997-04-03 |
1999-12-14 |
American Cyanamid Company |
Substituted 3-cyano quinolines
|
US6235883B1
(en)
|
1997-05-05 |
2001-05-22 |
Abgenix, Inc. |
Human monoclonal antibodies to epidermal growth factor receptor
|
CA2288705C
(en)
|
1997-05-06 |
2008-03-18 |
American Cyanamid Company |
Use of quinazoline compounds for the treatment of polycystic kidney disease
|
US6171586B1
(en)
|
1997-06-13 |
2001-01-09 |
Genentech, Inc. |
Antibody formulation
|
WO1998058964A1
(en)
|
1997-06-24 |
1998-12-30 |
Genentech, Inc. |
Methods and compositions for galactosylated glycoproteins
|
TW436485B
(en)
|
1997-08-01 |
2001-05-28 |
American Cyanamid Co |
Substituted quinazoline derivatives
|
WO1999022764A1
(en)
|
1997-10-31 |
1999-05-14 |
Genentech, Inc. |
Methods and compositions comprising glycoprotein glycoforms
|
HUP0004286A3
(en)
|
1997-11-06 |
2002-01-28 |
American Cyanamid Co Madison |
Use of quinazoline derivatives for producing pharmaceutical compositions for treating colonic polyps
|
US6610833B1
(en)
|
1997-11-24 |
2003-08-26 |
The Institute For Human Genetics And Biochemistry |
Monoclonal human natural antibodies
|
IL136544A0
(en)
|
1997-12-05 |
2001-06-14 |
Scripps Research Inst |
Humanization of murine antibody
|
RS49779B
(sr)
|
1998-01-12 |
2008-06-05 |
Glaxo Group Limited, |
Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
CA2323757C
(en)
|
1998-04-02 |
2011-08-02 |
Genentech, Inc. |
Antibody variants and fragments thereof
|
DK1071700T3
(da)
|
1998-04-20 |
2010-06-07 |
Glycart Biotechnology Ag |
Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
|
US6335155B1
(en)
|
1998-06-26 |
2002-01-01 |
Sunesis Pharmaceuticals, Inc. |
Methods for rapidly identifying small organic molecule ligands for binding to biological target molecules
|
EA003786B1
(ru)
|
1998-11-19 |
2003-10-30 |
Варнер Ламберт Компани |
N-[4-(3-хлор-4-фторфениламино)-7-(3-морфолин-4-илпропокси)хиназолин-6-ил]акриламид - необратимый ингибитор тирозинкиназ
|
EP1141708A1
(en)
|
1998-12-28 |
2001-10-10 |
Sunesis Pharmaceuticals Inc. |
Identifying small organic molecule ligands for binding
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
EP1141024B1
(en)
|
1999-01-15 |
2018-08-08 |
Genentech, Inc. |
POLYPEPTIDE COMPRISING A VARIANT HUMAN IgG1 Fc REGION
|
DK2270150T4
(da)
|
1999-04-09 |
2019-08-26 |
Kyowa Hakko Kirin Co Ltd |
Fremgangsmåde til at kontrollere aktiviteten af immunologisk funktionelt molekyle.
|
CA2388245C
(en)
|
1999-10-19 |
2012-01-10 |
Tatsuya Ogawa |
The use of serum-free adapted rat cells for producing heterologous polypeptides
|
UA72946C2
(ru)
|
1999-11-05 |
2005-05-16 |
Астразенека Аб |
Translated By PlajПРОИЗВОДНЫЕ ХИНАЗОЛИНА КАК ИНГИБИТОРЫ ВАСКУЛЯРНОГО ЭНДОТЕЛИАЛЬНОГО ФАКТОРА РОСТА (VEGF)
|
EP1240319A1
(en)
|
1999-12-15 |
2002-09-18 |
Genentech, Inc. |
Shotgun scanning, a combinatorial method for mapping functional protein epitopes
|
CA2395660A1
(en)
|
1999-12-29 |
2001-07-12 |
Immunogen, Inc. |
Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use
|
CN101289511A
(zh)
|
2000-04-11 |
2008-10-22 |
杰南技术公司 |
多价抗体及其应用
|
PL218428B1
(pl)
|
2000-10-06 |
2014-12-31 |
Kyowa Hakko Kogyo Kk |
Komórka, sposoby wytwarzania przeciwciał, leki zawierające przeciwciała, komórka CHO i przeciwciało klasy IgG
|
US6946292B2
(en)
|
2000-10-06 |
2005-09-20 |
Kyowa Hakko Kogyo Co., Ltd. |
Cells producing antibody compositions with increased antibody dependent cytotoxic activity
|
US7064191B2
(en)
|
2000-10-06 |
2006-06-20 |
Kyowa Hakko Kogyo Co., Ltd. |
Process for purifying antibody
|
US6596541B2
(en)
|
2000-10-31 |
2003-07-22 |
Regeneron Pharmaceuticals, Inc. |
Methods of modifying eukaryotic cells
|
DE60131456T2
(de)
|
2000-11-30 |
2008-07-10 |
Medarex, Inc., Milpitas |
Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern
|
KR20100018071A
(ko)
|
2001-08-03 |
2010-02-16 |
글리카트 바이오테크놀로지 아게 |
항체 의존적 세포 독성이 증가된 항체 글리코실화 변이체
|
GB0119249D0
(en)
|
2001-08-07 |
2001-10-03 |
Novartis Ag |
Organic compounds
|
KR100988949B1
(ko)
|
2001-10-25 |
2010-10-20 |
제넨테크, 인크. |
당단백질 조성물
|
US20040093621A1
(en)
|
2001-12-25 |
2004-05-13 |
Kyowa Hakko Kogyo Co., Ltd |
Antibody composition which specifically binds to CD20
|
EP1472265A4
(en)
|
2002-02-20 |
2005-06-15 |
Sirna Therapeutics Inc |
INHIBITION OF POLYCOMB GROUP PROTEIN EZH2 GENERATED BY RNA INTERFERENCE USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
RU2320331C2
(ru)
|
2002-03-04 |
2008-03-27 |
МЕРК ЭйчДиЭйСи Рисерч, ЛЛС. |
Способ индукции конечной дифференцировки
|
JPWO2003084569A1
(ja)
|
2002-04-09 |
2005-08-11 |
協和醗酵工業株式会社 |
抗体組成物含有医薬
|
CA2481657A1
(en)
|
2002-04-09 |
2003-10-16 |
Kyowa Hakko Kogyo Co., Ltd. |
Cells of which genome is modified
|
JPWO2003085118A1
(ja)
|
2002-04-09 |
2005-08-11 |
協和醗酵工業株式会社 |
抗体組成物の製造方法
|
US7749753B2
(en)
|
2002-04-09 |
2010-07-06 |
Kyowa Hakko Kirin Co., Ltd |
Cells in which activity of the protein involved in transportation of GDP-fucose is reduced or lost
|
AU2003236018A1
(en)
|
2002-04-09 |
2003-10-20 |
Kyowa Hakko Kirin Co., Ltd. |
METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcGamma RECEPTOR IIIa
|
US20050031613A1
(en)
|
2002-04-09 |
2005-02-10 |
Kazuyasu Nakamura |
Therapeutic agent for patients having human FcgammaRIIIa
|
NZ556507A
(en)
|
2002-06-03 |
2010-03-26 |
Genentech Inc |
Synthetic antibody phage libraries
|
US7361740B2
(en)
|
2002-10-15 |
2008-04-22 |
Pdl Biopharma, Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
GB0228900D0
(en)
|
2002-12-11 |
2003-01-15 |
Ml Lab Plc |
Cancer Immunotherapy
|
ES2347241T3
(es)
|
2002-12-16 |
2010-10-27 |
Genentech, Inc. |
Variantes de inmunoglobulina y sus utilizaciones.
|
AU2004205631A1
(en)
|
2003-01-16 |
2004-08-05 |
Genentech, Inc. |
Synthetic antibody phage libraries
|
US7871607B2
(en)
|
2003-03-05 |
2011-01-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
|
US20060104968A1
(en)
|
2003-03-05 |
2006-05-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
|
US20050106667A1
(en)
|
2003-08-01 |
2005-05-19 |
Genentech, Inc |
Binding polypeptides with restricted diversity sequences
|
US20060270730A1
(en)
|
2003-08-07 |
2006-11-30 |
Andreas Katopodis |
Histone deacetylase inhibitors as immunosuppressants
|
US20050059682A1
(en)
|
2003-09-12 |
2005-03-17 |
Supergen, Inc., A Delaware Corporation |
Compositions and methods for treatment of cancer
|
EP1688439A4
(en)
|
2003-10-08 |
2007-12-19 |
Kyowa Hakko Kogyo Kk |
HYBRID PROTEIN COMPOSITION
|
AU2004280065A1
(en)
|
2003-10-09 |
2005-04-21 |
Kyowa Hakko Kirin Co., Ltd. |
Process for producing antibody composition by using RNA inhibiting the function of alpha1,6-fucosyltransferase
|
US9296820B2
(en)
|
2003-11-05 |
2016-03-29 |
Roche Glycart Ag |
Polynucleotides encoding anti-CD20 antigen binding molecules with increased Fc receptor binding affinity and effector function
|
ES2697327T3
(es)
|
2003-11-06 |
2019-01-23 |
Seattle Genetics Inc |
Compuesto intermedio para la preparación de conjugados que comprenden derivados de auristatina y un enlazador
|
WO2005053742A1
(ja)
|
2003-12-04 |
2005-06-16 |
Kyowa Hakko Kogyo Co., Ltd. |
抗体組成物を含有する医薬
|
CN1961003B
(zh)
|
2004-03-31 |
2013-03-27 |
健泰科生物技术公司 |
人源化抗TGF-β抗体
|
EP1745022B1
(en)
|
2004-04-05 |
2014-08-13 |
Aton Pharma, Inc. |
Histone deacetylase inhibitor prodrugs
|
US7785903B2
(en)
|
2004-04-09 |
2010-08-31 |
Genentech, Inc. |
Variable domain library and uses
|
SG172616A1
(en)
|
2004-04-13 |
2011-07-28 |
Hoffmann La Roche |
Anti-p-selectin antibodies
|
US7795304B2
(en)
|
2004-08-25 |
2010-09-14 |
Merck Sharp & Dohme Corp. |
Histone deacetylase inhibitors
|
TWI380996B
(zh)
|
2004-09-17 |
2013-01-01 |
Hoffmann La Roche |
抗ox40l抗體
|
JP4948413B2
(ja)
|
2004-09-23 |
2012-06-06 |
ジェネンテック, インコーポレイテッド |
システイン操作抗体および結合体
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
KR101327323B1
(ko)
|
2005-01-14 |
2013-11-11 |
에스케이바이오팜 주식회사 |
옥사졸 하이드록삼산 유도체 및 이들의 용도
|
US20080182865A1
(en)
*
|
2005-03-11 |
2008-07-31 |
Witta Samir E |
Histone deacetylase inhibitors sensitize cancer cells to epidermal growth factor inhibitors
|
KR20080003334A
(ko)
*
|
2005-03-11 |
2008-01-07 |
더 리젠트스 오브 더 유니버시티 오브 콜로라도 |
암 세포를 표피 성장 인자 억제제에 대해 감작화시키는히스톤 데아세틸라제 억제제
|
EP1874755A4
(en)
|
2005-04-20 |
2010-04-28 |
Merck Sharp & Dohme |
BENZOTHIOPHENE-hydroxamic acid derivatives
|
EP2465870A1
(en)
|
2005-11-07 |
2012-06-20 |
Genentech, Inc. |
Binding polypeptides with diversified and consensus VH/VL hypervariable sequences
|
EP1973951A2
(en)
|
2005-12-02 |
2008-10-01 |
Genentech, Inc. |
Binding polypeptides with restricted diversity sequences
|
WO2007087129A2
(en)
|
2006-01-12 |
2007-08-02 |
Merck & Co., Inc. |
Fluorinated arylamide derivatives
|
GB0603041D0
(en)
|
2006-02-15 |
2006-03-29 |
Angeletti P Ist Richerche Bio |
Therapeutic compounds
|
EP2016101A2
(en)
|
2006-05-09 |
2009-01-21 |
Genentech, Inc. |
Binding polypeptides with optimized scaffolds
|
CA2651681A1
(en)
|
2006-05-18 |
2007-11-29 |
Merck & Co., Inc. |
Aryl-fused spirocyclic compounds
|
WO2007149782A2
(en)
|
2006-06-23 |
2007-12-27 |
University Of Medicine And Dentistry Of New Jersey |
Selective inhibitors for transferases
|
JP2009544611A
(ja)
|
2006-07-20 |
2009-12-17 |
メルク エンド カムパニー インコーポレーテッド |
ヒストン脱アセチル化酵素阻害剤としてのリン誘導体
|
DK2059533T3
(da)
|
2006-08-30 |
2013-02-25 |
Genentech Inc |
Multispecifikke antistoffer
|
CA2671649A1
(en)
|
2006-12-06 |
2008-06-12 |
Sapporo Medical University |
Potentiation of cellular immunity using histone deacetylase (hdac) inhibitors
|
US20080226635A1
(en)
|
2006-12-22 |
2008-09-18 |
Hans Koll |
Antibodies against insulin-like growth factor I receptor and uses thereof
|
WO2008127659A2
(en)
*
|
2007-04-13 |
2008-10-23 |
University Of Texas Southwestern Medical Center |
Combination therapy for cancer
|
CN100592373C
(zh)
|
2007-05-25 |
2010-02-24 |
群康科技(深圳)有限公司 |
液晶显示面板驱动装置及其驱动方法
|
WO2009005638A2
(en)
*
|
2007-06-27 |
2009-01-08 |
Merck & Co., Inc. |
Pyridyl and pyrimidinyl derivatives as histone deacetylase inhibitors
|
EP3103791B1
(en)
|
2007-06-27 |
2018-01-31 |
Merck Sharp & Dohme Corp. |
4-carboxybenzylamino derivatives as histone deacetylase inhibitors
|
DE102007032158A1
(de)
|
2007-07-02 |
2009-01-08 |
Eberhard-Karls-Universität Tübingen Universitätsklinikum |
Antitumormittel
|
WO2009006577A2
(en)
|
2007-07-03 |
2009-01-08 |
The Regents Of The University Of Michigan |
Compositions and methods for inhibiting ezh2
|
WO2009014941A1
(en)
|
2007-07-24 |
2009-01-29 |
Shenzen Chipscreen Bioscience, Ltd. |
3-(4-amidopyrrol-2-ylmethlidene)-2-indolinone derivatives as multi-target protein kinase inhibitors and histone deacetylase inhibitors
|
JP2010535766A
(ja)
|
2007-08-09 |
2010-11-25 |
メルク・シャープ・エンド・ドーム・コーポレイション |
ヒストン脱アセチル化酵素阻害剤としてのケイ素誘導体
|
TW200924777A
(en)
*
|
2007-09-14 |
2009-06-16 |
Methylgene Inc |
Combination therapy
|
JP2010540630A
(ja)
|
2007-10-04 |
2010-12-24 |
メルク・シャープ・エンド・ドーム・コーポレイション |
ヒストン脱アセチル化酵素阻害剤としてのn−ヒドロキシ−ナフタレンジカルボキサミド及びn−ヒドロキシ−ビフェニル−ジカルボキサミド化合物
|
DK2235064T3
(en)
|
2008-01-07 |
2016-01-11 |
Amgen Inc |
A process for the preparation of heterodimeric Fc molecules using electrostatic control effects
|
WO2009117831A1
(en)
|
2008-03-27 |
2009-10-01 |
The Royal Institution For The Advancement Of Learning/Mcgill University |
Hybrid molecules having mixed vitamin d receptor agonism and histone deacetylase inhibitory properties
|
EP2281031A2
(en)
|
2008-04-11 |
2011-02-09 |
University Of Southern California |
Methods and compositions for accelerating the generation of regulatory tcells ex vivo
|
WO2011103016A2
(en)
|
2010-02-19 |
2011-08-25 |
The Regents Of The University Of Michigan |
Compositions and methods for inhibiting ezh2
|
WO2011111072A2
(en)
|
2010-03-10 |
2011-09-15 |
Transgene Biotek Ltd. |
Adeno-associated virus ezh2 shrna (aav ezh2 shrna)therapy for breast cancer
|
UA110112C2
(ru)
|
2010-05-07 |
2015-11-25 |
Глаксосмітклайн Ллс |
Индолы
|
ES2528269T3
(es)
|
2010-05-07 |
2015-02-06 |
Glaxosmithkline Llc |
Azaindazoles
|
JP5864546B2
(ja)
|
2010-05-07 |
2016-02-17 |
グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーGlaxoSmithKline LLC |
インダゾール
|
EP2614369B1
(en)
*
|
2010-09-10 |
2016-02-03 |
Epizyme, Inc. |
Method for determining the suitability of inhibitors of human ezh2 in treatment
|
SG180031A1
(en)
*
|
2010-10-15 |
2012-05-30 |
Agency Science Tech & Res |
Combination treatment of cancer
|
JO3438B1
(ar)
|
2011-04-13 |
2019-10-20 |
Epizyme Inc |
مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
|
RU2014117632A
(ru)
*
|
2011-09-30 |
2015-11-10 |
ГЛЭКСОСМИТКЛАЙН ЭлЭлСи |
Способы лечения злокачественной опухоли
|
CA2870010C
(en)
*
|
2012-04-13 |
2023-02-21 |
Epizyme, Inc. |
Combination therapy for treating cancer
|
CN105307683A
(zh)
*
|
2013-03-14 |
2016-02-03 |
基因泰克公司 |
治疗癌症和预防癌症药物抗性的方法
|